George Juang, MD
Clinical Cardiac Electrophysiology · Flushing, NYNPI 1003802547
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $167,409 of the $197,563 with a category attached, or 84.7%. Johnson & Johnson accounts for 85.2% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2019 at $58,597 and has fallen 92.5% since, to $4,412 in 2025. Among clinical cardiac electrophysiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 719 payments — averaging $274.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$168K
- Biotronik Inc.$8K
- Sanofi-aventis U.S. LLC$7K
- Boston Scientific$2K
- Atricure, Inc.$2K
- Merck$1K
- plus $9K from 30 others
Across 11 payments — averaging $4400.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$32K
- Janssen Research & Development, LLC$12K
- Abbott$3K
- Boehringer Ingelheim$2K
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$167,40985%
- Travel & lodging$5,3843%
- Food & beverage$24,30512%
- Education$1660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 258 | $168,298 |
| Biotronik Inc. | 116 | $8,289 |
| Sanofi-aventis U.S. LLC | 34 | $7,182 |
| Boston Scientific | 12 | $2,190 |
| Atricure, Inc. | 10 | $1,674 |
| Merck | 38 | $1,248 |
| AstraZeneca | 36 | $1,092 |
| Kestra Medical Technology Services, Inc. | 13 | $1,014 |
| Janssen Research & Development, LLC | 9 | $868 |
| Amgen | 25 | $784 |
| Novartis | 31 | $677 |
| Medtronic(2 entities) | 9 | $606 |
| GSK | 21 | $513 |
| Altathera Pharmaceuticals LLC | 1 | $500 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $427 |
| Boehringer Ingelheim | 16 | $332 |
| E.r. Squibb & Sons, L.L.C. | 19 | $268 |
| Shockwave Medical, Inc | 1 | $228 |
| Novo Nordisk | 9 | $206 |
| Philips North America LLC | 4 | $150 |
| Medical Device Business Services, Inc. | 1 | $137 |
| Baxter Healthcare | 1 | $115 |
| Abiomed | 4 | $112 |
| Pfizer | 5 | $99 |
| AbbVie | 2 | $81 |
| Avanos Medical | 1 | $73 |
| Lexicon Pharmaceuticals, Inc. | 3 | $72 |
| Irhythm Technologies, Inc. | 3 | $61 |
| CSL Behring | 2 | $55 |
| Edwards Lifesciences | 2 | $49 |
| Chiesi USA, Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| Astellas Pharma US Inc | 2 | $28 |
| Abbott | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Terumo Medical Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$164,929
- MULTAQ$6,460
- VersaCross Access Solution$1,946
- Acticor 7 VR-T DX$1,787
- BioMonitor$1,510
- SYNERGY ABLATION SYSTEM$996
- Solia$795
- Acticor$795
- Edora$795
- Rivacor$795
- VERQUVO$616
- Assure WCD$592
- ISOLATOR SURGICAL ABLATION SYSTEM$557
- ATRICLIP LAA EXCLUSION SYSTEM$557
- DISSECTOR$557
- ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM$557
- Sotalol Hydrochloride$500
- Edora 8 DR-T$445
- Repatha$419
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$348
How this compares
$197,563 in reported general payments places this provider in the 90th percentile of 214 clinical cardiac electrophysiology providers in New York.
See all clinical cardiac electrophysiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MultaqDronedarone Hcl | 1,478 | $1,533,084 |
| XareltoRivaroxaban | 1,152 | $959,928 |
| FarxigaDapagliflozin Propanediol | 525 | $428,050 |
| EntrestoSacubitril/Valsartan | 458 | $393,062 |
| MounjaroTirzepatide | 261 | $294,502 |
| VascepaIcosapent Ethyl | 472 | $225,554 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 251 | $166,644 |
| EliquisApixaban | 188 | $161,059 |
| VerquvoVericiguat | 138 | $128,268 |
| Diclofenac Epolamine | 149 | $118,757 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 140 | $91,081 |
| RybelsusSemaglutide | 59 | $90,508 |
| Repatha SureclickEvolocumab | 105 | $64,396 |
| DapagliflozinDapagliflozin Propanediol | 67 | $39,933 |
| Varenicline Tartrate | 116 | $37,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCMultaq | $7,182 | $1,533,0841,478 claims |
| Johnson & JohnsonXarelto | $168,298 | $959,9281,152 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Airsupra, Symbicort | $1,092 | $614,281814 claims |
| NovartisEntresto | $677 | $393,062458 claims |
| PfizerEliquis | $99 | $161,059188 claims |
| MerckVerquvo | $1,248 | $128,268138 claims |
| Novo NordiskRybelsus, Ozempic | $206 | $109,47874 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $513 | $96,398153 claims |
| AbbVieLinzess | $81 | $11,13520 claims |
| Boehringer IngelheimPradaxa | $332 | $2,60213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 214 clinical cardiac electrophysiology providers in New York.
Other clinical cardiac electrophysiology in Flushing
- Seth GoldbargFlushing$60K
- Vivek ReddyNew York$14.9M
- Jacob KoruthNew York$3.7M
- Srinivas DukkipatiNew York$2.7M
- Amir AhmadiNew York$789K
- Larry ChinitzNew York$448K
- Felix YangBrooklyn$407K
- James IpNew York$347K
- Stavros MountantonakisManhasset$321K
- Jorge RomeroSyracuse$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.